To receive all Noxxon news in real time, contact [email protected]
Berlin, Germany, January 5, 2022, 7:30 p.m. CET – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing in the development of improved cancer treatments by targeting the tumor microenvironment (MET), today announces the end the evaluation of NOX-A12 by a leading pharmaceutical company in a non-oncological indication announced on June 24, 2019. The pharmaceutical company has decided not to continue its work with NOX-A12 in this area and to end the collaboration agreement. The targeted indication will not be disclosed.